• Kirin Holdings maintained its full-year forecast at its November 11, 2026, third-quarter results presentation, led by a company representative.
• Management expects fourth-quarter pressure from increased marketing spending, higher input costs and reversal of competitor-disruption benefits; restructuring charges also weigh on the outlook.
• Profit attributable to owners rose 43.3% to JPY 147.4 billion, supported by the Four Roses sale gain recognized in the second quarter.
• Normalized operating profit increased 18% to JPY 201.2 billion, driven by pharmaceuticals, Health Science growth and favorable exchange rates.
• The Jamieson Wellness acquisition remains on track for completion within the fiscal year; its financial impact is excluded from the forecast.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kirin Holdings Company Limited published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.